StratumSkin science, cited
Ingredient Index

Eczema · Barrier

Hydrocortisone

OTC topical corticosteroid, 0.5–1%

Overall grade BTypical strength 0.5–1% OTC; higher potencies prescription-only3 sources

The mildest, most widely available member of the topical corticosteroid family, and usually the first thing people reach for during a flare of eczema or dermatitis. The evidence for the corticosteroid class as a whole is about as deep as skincare evidence gets, though most of the direct efficacy data pools every potency together rather than isolating hydrocortisone's own strength. What the tube won't tell you is that it's also the weakest rung of that ladder: medium- and high-potency prescription steroids clear more people, faster, and courses are meant to be short rather than continuous.

Claim by claim

BEczema flares, short coursesAbout twice the response rate of vehicle alone in a pooled analysis of childhood eczema trials, though that analysis pooled every corticosteroid potency together rather than isolating hydrocortisone's own strength.
BCompared to stronger steroidsMedium- and high-potency options outperform low-potency hydrocortisone on treatment success, per the largest dosing review to date.
CContinuous, long-term useMeant for short courses, not daily use indefinitely. Twice-weekly maintenance after a flare clears prevents relapse without the thinning-skin trade-off of continuous use.

References

  1. Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic review and meta-analysis comparing topical corticosteroids with vehicle/moisturizer in childhood atopic dermatitis. Journal of Pediatric Nursing, 2019.AMeta-analysis of 12 RCTs, 2,224 children·65% responded to a topical corticosteroid, with every potency pooled together, against 32% for vehicle or moisturizer alone. This is evidence for the drug class rather than for the 1% OTC strength specifically, since potencies weren't separated out.PubMed 31026679
  2. Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database of Systematic Reviews, 2022.ACochrane review, 104 RCTs, 8,443 participants·Medium- and high-potency corticosteroids produced more treatment successes than low-potency options like hydrocortisone, with no added benefit from going beyond high potency. Once-daily application worked about as well as twice-daily. Twice-weekly maintenance after a flare cleared prevented relapse in roughly one of every three people treated, without raising side effects.PubMed 35275399DOI 10.1002/14651858.CD013356.pub2
  3. Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database of Systematic Reviews, 2024.ANetwork meta-analysis, 291 trials, 45,846 participants·Potent corticosteroids ranked among the most effective treatments in the whole network. Mild corticosteroids, hydrocortisone's own strength class, ranked less effective than the potent tier. Corticosteroids as a class had the lowest rate of application-site reactions of any treatment compared. Skin thinning wasn't detectable with short-term use, while longer use of six months to five years carried roughly a one-in-300 risk.PubMed 39219446DOI 10.1002/14651858.CD015064.pub2

Related condition hub

Eczema

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.